Catalyst Pharmaceuticals Inc. (Catalyst Pharmaceuticals), is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases.
Catalyst is currently developing amifampridine phosphate (with the proposed tradename of Firdapse®) for the treatment of Lambert - Eaton Myasthenic Syndrome (LEMS). LEMS is a rare, autoimmune, neuromuscular disorder in which the body attacks and
interferes with the communication between nerve and muscle cells primarily causing progressively severe muscle weakness and fatigue.
Catalyst has completed a 38 subject, pivotal phase III, global, multi-centered clinical trial and showed amifampridine phosphate to be safe and effective in the treatment of patients with LEMS.
Expanded Access Program
Catalyst Pharmaceuticals has announced the initiation of an Expanded Access Program (EAP) for amifampridine phosphate, which is a Phase IV open label study where patients who are diagnosed with LEMS or certain types of Congenital Myasthenic Syndromes
(CMS) and meet the inclusion and exclusion criteria can receive amifampridine phosphate (at no cost) when a patient's physician feels this investigational medication can help improve his or her condition. 1-844-347-3277 Read More
Catalyst Pharmaceuticals is also studying amifampridine phosphate in other neurological orphan indications including Congenital Myasthenic Syndromes (CMS), and Downbeat Nystagmus.
Other pipeline programs include CPP-115, which is under investigation in several neurological conditions such as post- traumatic stress disorders, Tourette’s disorders and infantile spasms. Read More